Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
I give below details of changes in the directors' interests in the Ordinary shares and American Depositary Shares (ADSs) of GlaxoSmithKline plc.
On 30 December 2011, the Company's Non-Executive Directors were provisionally allocated awards over Ordinary shares at a price of £14.70 per Ordinary share and $45.53 per ADS under the share allocation arrangements for Non-Executive Directors for the period of service from 1 October 2011 to 30 December 2011:
Non Executive Director
|
Ordinary Shares
|
American Depositary Shares (ADSs)
|
|
|
|
Sir Christopher Gent
|
2,295.918
|
|
|
|
|
Prof. Sir Roy Anderson
|
573.980
|
|
|
|
325.294
|
Dr Stephanie Burns
|
|
|
Ms Stacey Cartwright
|
318.878
|
|
Mr Lawrence Culp
|
|
650.588
|
|
|
|
Sir Crispin Davis
|
2,125.850
|
|
|
|
|
Ms Judy Lewent
|
|
503.763
|
Sir Deryck Maughan
|
|
650.588
|
|
|
|
Mr James Murdoch
|
1,275.510
|
|
|
|
|
Dr Daniel Podolsky
|
|
683.117
|
|
|
|
Mr Tom de Swaan
|
786.565
|
|
|
|
|
Sir Robert Wilson
|
573.980
|
|
The Company and the Non-Executive Directors were informed of these allocations on
3 January 2012.
This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
V A Whyte
Company Secretary
3 January 2012